ストックスクリーナーアプリを入手
183.60
2.82%
-5.33
プレマーケット:
181.13
-2.47
-1.35%
前日終値:
$188.93
開ける：
$188.14
24時間の取引高:
2.10M
Relative Volume:
0.44
時価総額：
$284.73B
収益：
$58.80B
当期純損益:
$10.24B
株価収益率:
56.00
EPS:
3.2788
ネットキャッシュフロー:
$8.98B
1週間 パフォーマンス:
-3.32%
1か月 パフォーマンス:
-10.09%
6か月 パフォーマンス:
+140.69%
1年 パフォーマンス:
+139.94%
1日の値動き範囲:
$182.62
$188.40
1週間の範囲:
$182.62
$193.96
52週間の値動き範囲:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
183.60 | 284.73B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
906.70 | 809.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.37 | 566.92B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.07 | 362.60B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
114.18 | 282.30B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca Data BreachLAPSUS$ Group Allegedly Claims Access to Internal Data - CyberSecurityNews
AstraZeneca PLC stock faces March pressure amid 100% YTD surge on NYSE - AD HOC NEWS
Signet Financial Management LLC Invests $2.57 Million in Astrazeneca Plc $AZN - MarketBeat
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
AstraZeneca plc stock faces pressure amid monthly declines but shows YTD strength in volatile pharma - AD HOC NEWS
Patterns Watch: Whats the outlook for AstraZeneca PLC Depositary Receipts sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn
AstraZeneca PLC (AZN) gains after successful Saphnelo trial - MSN
Hilltop National Bank Purchases 7,586 Shares of Astrazeneca Plc $AZN - MarketBeat
QP Wealth Management LLC Buys New Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Hacker Group LAPSUS$ Claims Alleged AstraZeneca Data Breach - Hackread
Form 6K AstraZeneca PLC ADR For: 20 March By Investing.com - Investing.com South Africa
AstraZeneca’s Pan-HER2 China Study Builds a Quiet Long-Term Edge in Oncology - TipRanks
AstraZeneca admits 45,750 new shares to London Stock Exchange main market - Investing.com
AstraZeneca (AZN) admits 45,750 new employee scheme shares to LSE - Stock Titan
Park National Corp OH Has $12.82 Million Stock Position in Astrazeneca Plc $AZN - MarketBeat
Miller Global Investments LLC Buys Shares of 7,716 Astrazeneca Plc $AZN - MarketBeat
2 Healthcare Stocks to Buy Before They Get Bought Out - The Motley Fool
Astrazeneca (NYSE:AZN) Rating Increased to Buy at Wall Street Zen - MarketBeat
AstraZeneca PLC stock faces pressure on NYSE amid insider filings and China expansion news - AD HOC NEWS
Moody's Changes Outlook on AstraZeneca to Positive on Organic Track Record - marketscreener.com
AstraZeneca (AZN) officer Mani Sharma details share and award holdings - Stock Titan
AstraZeneca Expands Real-World Push With New China Kidney Registry - TipRanks
AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook - TipRanks
AstraZeneca to boost cell therapy capabilities with new China investment - BioPharma Dive
Wilmington Savings Fund Society FSB Cuts Stock Position in Astrazeneca Plc $AZN - MarketBeat
Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca to build cell therapy base, innovation centre in Shanghai - marketscreener.com
AstraZeneca Makes Soliris Available In Malaysia For Rare Disease Treatment - bernama
Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026 - Meyka
AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer - Smartkarma
Why AstraZeneca Stock Was a Winner Today - MSN
AstraZeneca (AZN) Price Target Backed by Goldman After Baxdrostat Phase 3 Data - MSN
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims - GuruFocus
AZN Stock Quote Price and Forecast - CNN
Why AstraZeneca PLC (AZN) is one of the best immunotherapy stocks to buy according to hedge funds - MSN
Astrazeneca Plc $AZN Shares Sold by CIBC Private Wealth Group LLC - MarketBeat
AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach - TipRanks
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU - Yahoo Finance
AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical - MSN
Sentiment Recap: Why is AstraZeneca PLC Depositary Receipt stock going up2026 Market Trends & Fast Gain Swing Alerts - baoquankhu1.vn
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Rul - GuruFocus
Can AstraZeneca PLC Depositary Receipt expand into new marketsTrend Reversal & Real-Time Stock Entry Alerts - baoquankhu1.vn
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp - Insider Monkey
AstraZeneca receives EU approval for Imfinzi in early gastric cancer By Investing.com - Investing.com South Africa
AstraZeneca's Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer -- Update - marketscreener.com
EU backs AstraZeneca (NYSE: AZN) Imfinzi for early gastric and GEJ cancers - Stock Titan
AstraZeneca (AZN) Gains EU Approval for Imfinzi in Cancer Treatm - GuruFocus
AstraZeneca PLC Stock (ISIN: US6549022043) Gains Momentum on EU Imfinzi Approval for Gastric Cancer - AD HOC NEWS
EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer - marketscreener.com
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
0.02%
大文字化:
|
ボリューム (24 時間):